NASDAQ:CDTXCidara Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Cidara Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $3.62 +0.04 (+1.12 %) (As of 05/29/2020 04:00 PM ET) Add Compare Share Today's Range$3.37Now: $3.62▼$3.6550-Day Range$2.45MA: $2.99▼$3.6352-Week Range$1.22Now: $3.62▼$4.44Volume158,369 shsAverage Volume261,409 shsMarket Capitalization$147.52 millionP/E RatioN/ADividend YieldN/ABeta1.85 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Cidara Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-infectives for the treatment of diseases. Its lead product candidate is rezafungin acetate, a molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, fungal infections associated with high mortality rates. It is also developing antibody-drug conjugates for multidrug-resistant bacterial infections that directly kill pathogens and also direct a patient's immune system to attack and eliminate bacterial, fungal, or viral pathogens. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in June 2014. Cidara Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.Read More Beat the Market (BTM) Rank™ 3.4 Analyst's Opinion Consensus RatingCidara Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.71, and is based on 6 buy ratings, no hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.75, Cidara Therapeutics has a potential upside of 86.5% from its current price of $3.62.Amount of Analyst CoverageCidara Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 2.8 Community Rank Outperform VotesCidara Therapeutics has received 381 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCidara Therapeutics has received 291 “underperform” votes. (Add your “underperform” vote.)Community SentimentCidara Therapeutics has received 56.70% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Cidara Therapeutics and other stocks. Vote “Outperform” if you believe CDTX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CDTX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCidara Therapeutics does not currently pay a dividend.Dividend GrowthCidara Therapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cidara Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 15.28% of the stock of Cidara Therapeutics is held by insiders.Percentage Held by Institutions55.14% of the stock of Cidara Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Cidara Therapeutics are expected to decrease in the coming year, from ($1.49) to ($1.87) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cidara Therapeutics is -2.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cidara Therapeutics is -2.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCidara Therapeutics has a P/B Ratio of 2.74. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.4Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.43 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CDTX Previous Symbol CUSIPN/A CIK1610618 Webwww.cidara.com Phone858-752-6170Debt Debt-to-Equity Ratio0.01 Current Ratio2.72 Quick Ratio2.72Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$20.92 million Price / Sales7.05 Cash FlowN/A Price / Cash FlowN/A Book Value$1.32 per share Price / Book2.74Profitability EPS (Most Recent Fiscal Year)($1.41) Net Income$-41,090,000.00 Net MarginsN/A Return on Equity-97.10% Return on Assets-58.40%Miscellaneous Employees68 Outstanding Shares40,750,000Market Cap$147.52 million Next Earnings Date8/13/2020 (Estimated) OptionableOptionable NASDAQ:CDTX Rates by TradingView Receive CDTX News and Ratings via Email Sign-up to receive the latest news and ratings for CDTX and its competitors with MarketBeat's FREE daily newsletter. Cidara Therapeutics (NASDAQ:CDTX) Frequently Asked Questions How has Cidara Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Cidara Therapeutics' stock was trading at $2.48 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CDTX stock has increased by 46.0% and is now trading at $3.62. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Cidara Therapeutics? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cidara Therapeutics in the last year. There are currently 1 sell rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Cidara Therapeutics. When is Cidara Therapeutics' next earnings date? Cidara Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Cidara Therapeutics. How were Cidara Therapeutics' earnings last quarter? Cidara Therapeutics Inc (NASDAQ:CDTX) announced its earnings results on Wednesday, May, 13th. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.34) by $0.12. The biotechnology company had revenue of $2.53 million for the quarter, compared to analyst estimates of $5 million. View Cidara Therapeutics' earnings history. What price target have analysts set for CDTX? 7 brokerages have issued twelve-month price objectives for Cidara Therapeutics' shares. Their forecasts range from $4.00 to $10.00. On average, they expect Cidara Therapeutics' stock price to reach $6.75 in the next year. This suggests a possible upside of 86.5% from the stock's current price. View analysts' price targets for Cidara Therapeutics. Has Cidara Therapeutics been receiving favorable news coverage? Media coverage about CDTX stock has been trending somewhat positive on Saturday, InfoTrie Sentiment reports. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Cidara Therapeutics earned a news sentiment score of 2.0 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutCidara Therapeutics. Who are some of Cidara Therapeutics' key competitors? Some companies that are related to Cidara Therapeutics include Prevail Therapeutics (PRVL), Aptose Biosciences (APTO), MeiraGTx (MGTX), Scholar Rock (SRRK), DBV TECHNOLOGIE/S (DBVT), Harpoon Therapeutics (HARP), Rubius Therapeutics (RUBY), Innate Pharma (IPHYF), Agenus (AGEN), Autolus Therapeutics (AUTL), Voyager Therapeutics (VYGR), PDL BioPharma (PDLI), Precision BioSciences (DTIL), Eiger Biopharmaceuticals (EIGR) and Verona Pharma (TARA). View all competitors. What other stocks do shareholders of Cidara Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cidara Therapeutics investors own include Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Gilead Sciences (GILD), VBI Vaccines (VBIV), Clovis Oncology (CLVS), Crispr Therapeutics (CRSP), Verastem (VSTM), Dynavax Technologies (DVAX), Micron Technology (MU) and Sanofi (SNY). Who are Cidara Therapeutics' key executives? Cidara Therapeutics' management team includes the following people: Dr. Jeffrey L. Stein, Pres, CEO & Exec. Director (Age 64)Dr. Taylor Sandison, Chief Medical Officer (Age 47)Dr. Kevin M. Forrest Ph.D., Founder and Chief Strategy Officer (Age 42)Mr. James E. Levine, Chief Financial Officer (Age 48)Mr. Paul Daruwala, COO & Chief Commercial Officer (Age 50) When did Cidara Therapeutics IPO? (CDTX) raised $60 million in an IPO on Wednesday, April 15th 2015. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Jefferies and Leerink Partners acted as the underwriters for the IPO and Wedbush PacGrow Life Sciences, Needham and BTIG were co-managers. What is Cidara Therapeutics' stock symbol? Cidara Therapeutics trades on the NASDAQ under the ticker symbol "CDTX." Who are Cidara Therapeutics' major shareholders? Cidara Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Stonepine Capital Management LLC (3.20%), Alethea Capital Management LLC (2.20%), Granahan Investment Management Inc. MA (1.41%), West Family Investments Inc. (0.91%), Geode Capital Management LLC (0.54%) and Tekla Capital Management LLC (0.48%). Company insiders that own Cidara Therapeutics stock include James E Levine, Jeffrey Stein, Jessica Oien, Neil Abdollahian and Paul Daruwala. View institutional ownership trends for Cidara Therapeutics. Which major investors are buying Cidara Therapeutics stock? CDTX stock was acquired by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC, Alethea Capital Management LLC, Acadian Asset Management LLC, Granahan Investment Management Inc. MA, Geode Capital Management LLC, Two Sigma Investments LP, West Family Investments Inc., and Russell Investments Group Ltd.. Company insiders that have bought Cidara Therapeutics stock in the last two years include James E Levine, and Jeffrey Stein. View insider buying and selling activity for Cidara Therapeutics. How do I buy shares of Cidara Therapeutics? Shares of CDTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Cidara Therapeutics' stock price today? One share of CDTX stock can currently be purchased for approximately $3.62. How big of a company is Cidara Therapeutics? Cidara Therapeutics has a market capitalization of $147.52 million and generates $20.92 million in revenue each year. The biotechnology company earns $-41,090,000.00 in net income (profit) each year or ($1.41) on an earnings per share basis. Cidara Therapeutics employs 68 workers across the globe. What is Cidara Therapeutics' official website? The official website for Cidara Therapeutics is www.cidara.com. How can I contact Cidara Therapeutics? Cidara Therapeutics' mailing address is 6310 NANCY RIDGE DRIVE SUITE 101, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-752-6170 or via email at [email protected] This page was last updated on 5/30/2020 by MarketBeat.com Staff
